Guggenheim analyst Yatin Suneja raised the firm’s price target on Abivax (ABVX) to $175 from $150 and keeps a Buy rating on the shares based on the firm’s “optimistic outlook” for obefazimod in the 44-week maintenance readout that is upcoming.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax price target raised to $142 from $112 at Piper Sandler
- Abivax price target raised to $131 from $114 at Citizens
- Abivax SA Reports Increased Losses in Q3 2025 Amid Rising R&D Costs
- Options Volatility and Implied Earnings Moves Today, December 15, 2025
- Options Volatility and Implied Earnings Moves This Week, December 15 – December 19, 2025